This issue of Hematology/Oncology Clinics, edited by Drs. Jorge J. Castillo, Efstathios Kastritis, and Steven P. Treon, will focus on Waldenström Macroglobulinemia. Topics include, but are not limited to, Genomics; Epigenomics; Flow cytometry; Marrow microenvironment; Familial Waldenstrom; MYD88 L265P and other MYD88 mutations; CXCR4 and other recurrent mutations; Diagnosis and differential diagnosis; Criteria to treat and treatment goals; Alkylators; Monoclonal antibodies; Proteasome inhibitors; BTK inhibitors; Transplant; and Novel approaches.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. xi 7. Preface - p. xiii 8. Genomic Landscape of Waldenström Macroglobulinemia - p. 745 9. Working Toward a Genomic Prognostic Classification of Waldenström Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and Beyond - p. 753 10. Flow Cytometry - p. 765 11. The Bone Marrow Microenvironment in Waldenström Macroglobulinemia - p. 777 12. Familial Waldenström Macroglobulinemia: Families Informing Populations - p. 787 13. Initial Evaluation of the Patient with Waldenström Macroglobulinemia - p. 811 14. Alkylating Agents in the Treatment of Waldenström Macroglobulinemia - p. 821 15. Proteasome Inhibitors in Waldenström Macroglobulinemia - p. 829 16. Monoclonal Antibodies for Waldenström Macroglobulinemia - p. 841 17. First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia - p. 853 18. High-Dose Therapy and Hematopoietic Stem Cell Transplantation in Waldenström Macroglobulinemia - p. 865 19. Novel Approaches in Waldenström Macroglobulinemia - p. 875
No hay muestra disponible
No hay ficha técnica disponible
This issue of Hematology/Oncology Clinics, edited by Drs. Jorge J. Castillo, Efstathios Kastritis, and Steven P. Treon, will focus on Waldenström Macroglobulinemia. Topics include, but are not limited to, Genomics; Epigenomics; Flow cytometry; Marrow microenvironment; Familial Waldenstrom; MYD88 L265P and other MYD88 mutations; CXCR4 and other recurrent mutations; Diagnosis and differential diagnosis; Criteria to treat and treatment goals; Alkylators; Monoclonal antibodies; Proteasome inhibitors; BTK inhibitors; Transplant; and Novel approaches.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. xi 7. Preface - p. xiii 8. Genomic Landscape of Waldenström Macroglobulinemia - p. 745 9. Working Toward a Genomic Prognostic Classification of Waldenström Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and Beyond - p. 753 10. Flow Cytometry - p. 765 11. The Bone Marrow Microenvironment in Waldenström Macroglobulinemia - p. 777 12. Familial Waldenström Macroglobulinemia: Families Informing Populations - p. 787 13. Initial Evaluation of the Patient with Waldenström Macroglobulinemia - p. 811 14. Alkylating Agents in the Treatment of Waldenström Macroglobulinemia - p. 821 15. Proteasome Inhibitors in Waldenström Macroglobulinemia - p. 829 16. Monoclonal Antibodies for Waldenström Macroglobulinemia - p. 841 17. First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia - p. 853 18. High-Dose Therapy and Hematopoietic Stem Cell Transplantation in Waldenström Macroglobulinemia - p. 865 19. Novel Approaches in Waldenström Macroglobulinemia - p. 875
No hay muestra disponible
No hay ficha técnica disponible
